Figure 3.
OS depending on the presence and dynamic of molecular parameters on midostaurin. (A) Kaplan-Meier estimates of OS depending on mutational status in the SRSF2/ASXL1/RUNX1 (S/A/R) gene panel (S/A/Rpos vs S/A/Rneg) at baseline. (B) OS depending on the expressed KIT D816V allele burden (EAB) reduction at month 6 in PB (≥25% vs <25%). HR, hazard ratio 95% confidence interval; NR, not reached.